Novo Nordisk (NVO) valuation

Run six valuation models on Novo Nordisk with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

NVO
NVO

Novo Nordisk

NVO · Healthcare

Current price

46,25 DKK

You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
DKK 202.61B
PE (TTM | NTM | +1y)
11.39 | 13.79 | 2.13
Price / Sales
0.62
EV / EBITDA
1.75
Price / Book
6.60

Cash flow

FCF yield(11.39 / 46.24)
+24.64%
SBC-adjusted FCF yield
SBC impact

Margins & growth

Profit margin
+35.35%
Operating margin
+42.54%
Quarterly earnings (YoY)
-20.81%
Quarterly revenue (YoY)
+2.12%

Balance

Cash
DKK 44.98B
Debt
DKK 140.13B
Net position
-DKK 95.14B

Dividend

Dividend yield
+3.81%
Payout ratio
+44.46%
Next payout
8/25/2026

Price (1 year)

-11.76%
DKK 62.33

Revenue

estimate
Q2 25: DKK 76.86BQ2 25Q3 25: DKK 74.98BQ3 25Q4 25: DKK 79.14BQ4 25Q1 26: DKK 96.82BQ1 26Q2 26: DKK 78.49BQ2 26Q3 26 · estimate: DKK 72.91BQ3 26DKK 96.82B

EBITDA

Q2 25: DKK 43.6BQ2 25Q3 25: DKK 31.44BQ3 25Q4 25: DKK 37.3BQ4 25Q1 26: DKK 69.21BQ1 26Q2 26: DKK 38.68BQ2 26DKK 69.21B

Net income

Q2 25: DKK 26.5BQ2 25Q3 25: DKK 20.01BQ3 25Q4 25: DKK 26.89BQ4 25Q1 26: DKK 48.56BQ1 26Q2 26: DKK 20.99BQ2 26DKK 48.56B

Free cash flow

Q2 25: DKK 25.5BQ2 25Q3 25: DKK 29.56BQ3 25Q4 25: -DKK 36.22BQ4 25Q1 26: DKK 12.05BQ1 26Q2 26: DKK 42.4BQ2 26DKK 42.4B

EPS

estimate
Q2 25: 5.96Q2 25Q3 25: 4.50Q3 25Q4 25: 6.04Q4 25Q1 26: 10.91Q1 26Q2 26: 4.74Q2 26Q3 26 · estimate: 5.14Q3 2610.91

Cash & debt

CashDebt
Q2 25 · Cash: DKK 18.44BQ2 25 · Debt: DKK 99.27BQ2 25Q3 25 · Cash: DKK 32.08BQ3 25 · Debt: DKK 101.21BQ3 25Q4 25 · Cash: DKK 26.46BQ4 25 · Debt: DKK 130.96BQ4 25Q1 26 · Cash: DKK 21.13BQ1 26 · Debt: DKK 146.38BQ1 26Q2 26 · Cash: DKK 44.48BQ2 26 · Debt: DKK 140.13BQ2 26DKK 146.38B

Return of capital

DividendsBuybacks
Q2 25 · Dividends: DKK 174MQ2 25Q3 25 · Dividends: DKK 16.66BQ3 25Q1 26 · Dividends: DKK 35.31BQ1 26 · Buybacks: DKK 2.4BQ1 26Q2 26 · Buybacks: DKK 3.5BQ2 26DKK 37.71B

Shares outstanding

Q2 25: 4.44BQ2 25Q3 25: 4.44BQ3 25Q4 25: 4.44BQ4 25Q1 26: 4.44BQ1 26Q2 26: 4.42BQ2 264.44B

Operating expenses

R&DSG&A
Q2 25 · R&D: DKK 11.69BQ2 25 · SG&A: DKK 18.85BQ2 25Q3 25 · R&D: DKK 15.39BQ3 25 · SG&A: DKK 17.88BQ3 25Q4 25 · R&D: DKK 14.65BQ4 25 · SG&A: DKK 17.44BQ4 25Q1 26 · R&D: DKK 10.28BQ1 26 · SG&A: DKK 13.22BQ1 26Q2 26 · R&D: DKK 17.79BQ2 26 · SG&A: DKK 16.31BQ2 26DKK 34.09B

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Other comparisons

Popular companies